Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000652:urine; D000284:Administration, Oral; D000368:Aged; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000652:urine; D004305:Dose-Response Relationship, Drug; D005260:Female; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D007263:Infusions, Parenteral; D007980:Levodopa / Q000008:administration & dosage / Q000378:metabolism* / Q000652:urine; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy / Q000378:metabolism / Q000652:urine; D014316:Tritium
D014316:Tritium; D015102:3,4-Dihydroxyphenylacetic Acid; D007980:Levodopa; D004298:Dopamine; D006719:Homovanillic Acid